DE1450454U
(enrdf_load_stackoverflow )
Havlir et al.
1998
Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS
Kumana et al.
2002
Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies
Begley et al.
2020
Lenacapavir sustained delivery formulation supports 6-month dosing interval
SK423889A3
(en )
1997-11-05
Pharmaceutical mixture for the prevention of veneral diseases
Reynes et al.
2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals
Lo et al.
1999
Fungal peritonitis-current status 1998
WO2021164891A1
(de )
2021-08-26
Modulare schutzbekleidungseinheit sowie deren verwendung
US20200348108A1
(en )
2020-11-05
Ballistic shield and method of using multiple interconnected ballistic shields to protect a group of individuals
Segal-Maurer et al.
2021
Potent antiviral activity of lenacapavir in phase 2/3 in heavily art-experienced PWH
Yilmaz et al.
2018
In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates
Clay et al.
1979
Enthalpies of formation and solution of macrocyclic and noncyclic tetraaza ligands. Origins of the enthalpy term in the macrocyclic effect
Lee et al.
2010
Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma
Gaddoni et al.
1993
Contact dermatitis among decorators and enamellers in hand-made ceramic decorations.
Neufeld et al.
1943
Biochemical Findings in Normal and Trauma-Resistant Rats Following Trauma.
DE1517474U
(enrdf_load_stackoverflow )
Murskyj
2020
Disseminated histoplasmosis after vedolizumab treatment for ulcerative colitis
Hoesley et al.
1997
Overview of oral azole drugs as systemic antifungal therapy
Woods et al.
1995
Methoclocinnamox: a μ partial agonist with pharmacotherapeutic potential for heroin abuse
DE1502554U
(enrdf_load_stackoverflow )
ES2304163T3
(es )
2008-09-16
Solucion inyectable esteril estable, lista para usar, de 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amina-1h-purin-6(9h)-ona; sistema cerrado para envasar solucion; procedim. eliminar residuos alcalinos cristales de 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amina-1h-purin-6(9h)-ona.
CN211584289U
(zh )
2020-09-29
一种新型便于艾滋病人使用的药盒
Prugnard et al.
1996
Chemistry and structure-activity relationships of biguanides
CN215641145U
(zh )
2022-01-25
化学品物理危险性鉴定用远距检测装置
PRUGNARD et al.
2013
C. Structure-Activity Relationships